Dalzanemdor

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

The FDA approved Bristol Myers Squibb’s Cobenfy, the first novel schizophrenia treatment in 35 years, marking a significant triumph in neuroscience.

The FDA has agreed that existing Phase I/II data for uniQure's AMT-130, compared to external controls, can support a Biologics License Application for accelerated approval.

Novartis and PTC Therapeutics have entered into a collaboration for the development and commercialization of PTC518, a potential treatment for Huntington's disease.

Sage Therapeutics' dalzanemdor failed in the Phase II DIMENSION trial for Huntington's disease, leading to the discontinuation of its development.